218
Participants
Start Date
August 14, 2019
Primary Completion Date
August 31, 2026
Study Completion Date
August 31, 2029
Ipilimumab
Ipilimumab 3mg per kg every 3 weeks for 4 doses
Nivolumab
Nivolumab 1mg/kg every 3 weeks for 4 doses, then 480mg every 4 weeks.
Stereotactic Radiotherapy
The first dose of immunotherapy Must be given prior to the start of radiotherapy. One fraction at between 16 to 22 Gy or 24 to 30 Gy hypofractionated for larger lesions.
Salvage therapy
Any form of salvage therapy (surgery or radiotherapy) for intracranial disease progression, further disease control at any site, symptom control or treatment of cerebral haemorrhage or cerebral radionecrosis.
RECRUITING
Melanoma Institute Australia, Wollstonecraft
RECRUITING
Westmead Hospital, Sydney
RECRUITING
Calvary Mater NewcastleHospital, Waratah
RECRUITING
Peter MacCallum Cancer Centre, East Melbourne
RECRUITING
Alfred Hospital, Melbourne
RECRUITING
Princess Alexandra Hospital, Woolloongabba
RECRUITING
Royal Adelaide Hospital, Adelaide
RECRUITING
Sir Charles Gairdner Hosptial, Perth
RECRUITING
Oslo Univesity Hospital Radiumhospitalet, Oslo
NOT_YET_RECRUITING
Skåne University Hospital, Lund
Collaborators (1)
Bristol-Myers Squibb
INDUSTRY
Melanoma Institute Australia
OTHER